Evaluation of the Prevalence of Anti-transglutaminase 2 and 6 Antibodies in Patients with Sero-Positive Multiple Sclerosis.

Q3 Medicine

Middle East Journal of Digestive Diseases Pub Date : 2024-01-01 Epub Date: 2024-01-31 DOI:10.34172/mejdd.2024.368

Mohammad Hassan Emami, Mohammad Reza Najafi, Sepideh Allahdadian, Samane Mohammadzadeh, Nahid Jamali, Anasik Lalazarian, Vahid Shaygan Nejad, Fatemeh Maghool

{"title":"Evaluation of the Prevalence of Anti-transglutaminase 2 and 6 Antibodies in Patients with Sero-Positive Multiple Sclerosis.","authors":"Mohammad Hassan Emami, Mohammad Reza Najafi, Sepideh Allahdadian, Samane Mohammadzadeh, Nahid Jamali, Anasik Lalazarian, Vahid Shaygan Nejad, Fatemeh Maghool","doi":"10.34172/mejdd.2024.368","DOIUrl":null,"url":null,"abstract":"Background: Gluten sensitivity (GS) is one of the gluten-related disorders (GRDs). Patients with GS may have serum antibodies against tissue transglutaminase (tTG) (IgA and IgG) without any evidence of enteropathy. We aimed to evaluate both tTG-6 and tTG-2 antibodies to determine the prevalence of seropositive tTG-2 and tTG-6 antibodies in patients with multiple sclerosis (MS).Methods: In this cross-sectional study, we carried out serological tests (IgA & IgG anti-tTG-6 and tTG-2 antibodies) in patients with MS.Results: Seventy-two patients with MS were included in this study. Of them, seropositive patients for total (IgA+IgG) of tTG-6 and tTG-2 autoantibodies were 9.7% (95% CI, 4.2-18) and 5.6% (95% CI, 1.4-12.5), respectively.Conclusion: Anti-tTG-6 antibody testing may be necessary for early diagnosis of GS in patients with MS. More studies with larger sample sizes are warranted to confirm these data.","PeriodicalId":18517,"journal":{"name":"Middle East Journal of Digestive Diseases","volume":"16 1","pages":"47-51"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264836/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East Journal of Digestive Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/mejdd.2024.368","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Gluten sensitivity (GS) is one of the gluten-related disorders (GRDs). Patients with GS may have serum antibodies against tissue transglutaminase (tTG) (IgA and IgG) without any evidence of enteropathy. We aimed to evaluate both tTG-6 and tTG-2 antibodies to determine the prevalence of seropositive tTG-2 and tTG-6 antibodies in patients with multiple sclerosis (MS).

Methods: In this cross-sectional study, we carried out serological tests (IgA & IgG anti-tTG-6 and tTG-2 antibodies) in patients with MS.

Results: Seventy-two patients with MS were included in this study. Of them, seropositive patients for total (IgA+IgG) of tTG-6 and tTG-2 autoantibodies were 9.7% (95% CI, 4.2-18) and 5.6% (95% CI, 1.4-12.5), respectively.

Conclusion: Anti-tTG-6 antibody testing may be necessary for early diagnosis of GS in patients with MS. More studies with larger sample sizes are warranted to confirm these data.

查看原文本刊更多论文

评估血清阳性多发性硬化症患者中抗转谷氨酰胺酶 2 和 6 抗体的流行率

背景：麸质敏感症（GS）是麸质相关疾病（GRD）之一。麸质过敏症患者的血清中可能存在针对组织转谷氨酰胺酶（tTG）的抗体（IgA 和 IgG），但没有任何肠病的证据。我们旨在评估 tTG-6 和 tTG-2 抗体，以确定多发性硬化症（MS）患者血清中 tTG-2 和 tTG-6 抗体阳性的发生率：在这项横断面研究中，我们对多发性硬化症患者进行了血清学检测（抗tTG-6和tTG-2抗体的IgA和IgG）：结果：72 名多发性硬化症患者参与了这项研究。其中，tTG-6和tTG-2自身抗体总和（IgA+IgG）血清阳性患者分别为9.7%（95% CI，4.2-18）和5.6%（95% CI，1.4-12.5）：结论：抗-tTG-6抗体检测可能是早期诊断多发性硬化症患者GS的必要手段。需要更多样本量更大的研究来证实这些数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊